Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000787 | Angina Pectoris NIH | 0.71 |
| D054143 | Heart Failure, Systolic NIH | 0.71 |
| D054058 | Acute Coronary Syndrome NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001681 | Angina pectoris HPO | 0.71 |
| HP:0001677 | Coronary artery atherosclerosis HPO | 0.33 |
| HP:0001635 | Congestive heart failure HPO | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001658 | Myocardial infarction HPO | 0.22 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
The goal of this pilot study is to determine if a home based bicycle exercise program can significantly improve the exercise tolerance and well being of pulmonary outpatients. The investigators will use a computer based monitoring system to allow us to speak with participants, view participants, and track patient bicycle activity (speed, duration of exercise, rate of work) during exercise sessions. The investigators plan to have participants perform three telemonitored exercise sessions per week for 12 weeks as part of this program. The investigators will assess exercise performance on the bicycle, called a work rate test, at the beginning of the program and then again at 6 weeks and 12 weeks into the program to determine if the program can produce a clinically significant improvement in work rate test performance (i.e. a greater than 1.15 minute increase in exercise duration at an 80% work rate). The investigators will also assess participant CRQ, SPPB scores and SF36 scores (indices of patient well being) at baseline, at 6 weeks, and at 12 weeks, to determine if the exercise program elicits an increase in these indices.
Description: This will measure changes in the time the subject can exercise at 80% of the maximum work rate.
Measure: 80% work rate test Time: This will be measured at baseline, at 6 weeks, and at 12 weeks. The primary outcome measure to be assessed is the change in the 80% work rate test time between the initial and 12 week assessment.Description: this will ask how short of breath the subject is: Scores will range from 20 to 140, the higher the score, the better the patient's condition
Measure: CRQ score: Chronic Respiratory Questionnaire Time: baseline and at 6 weeks and 12 weeksDescription: this questionnaire will ask about quality of life; each question scores from 1 to 6; the higher the score, the worse the patients' condition
Measure: SF36: Short Form Survey; 36 Questions Time: baseline and at 6 weeks and 12 weeksDescription: this will test the ability to perform simple movements; balance will be scores 0 to 4, gait speed 2 to 8, and chair standing 0 to 4; the higher the score, the better the patient's condition
Measure: SPPB: Short Physical Performance Battery Time: baseline and at 6 weeks and 12 weeksAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports